📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. (2021)

First Author: Jonasch E

Attributed to: Development of a 'humanised' model for renal cancer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1056/nejmoa2103425

PubMed Identifier: 34818478

Publication URI: http://europepmc.org/abstract/MED/34818478

Type: Journal Article/Review

Volume: 385

Parent Publication: The New England journal of medicine

Issue: 22

ISSN: 0028-4793